[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Alemão Oswaldo Cruz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,84,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100602067","brazilian-registry-of-chronic-non-communicable-diseases-in-people-living-with-hivaids-100602067",false,"NCT07118683","BRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV\u002FAIDS","BRAVO","Inclusion Criteria:\n\n* Adults aged 18 or over;\n* Confirmed HIV or AIDS diagnosis;\n* Signature of consent form.\n\nExclusion Criteria:\n\n* Indigenous population or those in prison in open or closed regimes;\n* Patients hospitalized at the time of signing the Consent Form.","ALL","18 Years",{"count":19,"type":20},743,"ESTIMATED","3 Months","OBSERVATIONAL","BRAVO proposes the establishment of a comprehensive registry of chronic noncommunicable diseases (NCDs), providing crucial data for the formulation of effective health policies for people living with HIV\u002FAIDS (PLWHA). BRAVO is a cross-sectional study, that will collect on the study allocation sociodemographic data, risk factors related to the main NCDs, physical examination data and samples for determination of biochemical and metabolic parameters. To this end, the study will include co-participating research centers from the 5 Brazilian geographic macro-regions.",[25,26,27,28,29],"AIDS (Acquired Immunodeficiency Syndrome)","Cardiovascular and Cerebrovascular Diseases","Respiratory Comorbidities","Chronic Kidney Disease","Cancer",[31,32,33,34,35,36,37,38,39,40],"Acquired Immunodeficiency Syndrome","Cardiovascular Diseases","Respiratory Tract Diseases","Renal Insufficiency, Chronic","Neoplasms","Treatment Adherence and Compliance","Quality of Life","Prevalence","Brazil","Cross-sectional study","RECRUITING","2026-05-19",{"date":44,"type":45},"2026-05-22","ACTUAL",{"date":47,"type":45},"2025-08-15",{"date":49,"type":20},"2026-12",{"name":51,"class":52},"Hospital Alemão Oswaldo Cruz","OTHER",9,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100574606","leprosy-active-searching-trial-in-brazil-100574606","NCT06761469","Leprosy Active Searching Trial in Brazil","Pragmatic, Randomized, Cluster Stepped-Wedge Clinical Trial for Active Case Finding of Leprosy in Brazil","LAST•Br","Inclusion Criteria:\n\n(I) Municipalities\n\n* Municipality recognized by the Brazilian Institute of Geography and Statistics as part of the Brazilian Federation.\n* Municipality with operational epidemiological classification by the Ministry of Health (BMoH) as: 'municipalities with cases in the period from 2015 to 2019'.\n* Municipality with authorization\u002Fconsent from the government to participate in the study.\n\n(II) Primary Health Units (Unidade Básica de Saúde or UBS) • UBS with territorial coverage (linked population) within the participating municipality.\n\n(III) Participants\n\n• Patients with positive Leprosy Suspicion Questionnaire (LSQ): children under five years old with Free and Informed Consent Form (ICF) signed by parents\u002Fguardians, 5-17 years old with ICF signed by parents\u002Fguardians and Free and Informed Assent Form (IAF) signed by the minor, and patients over 18 years old with ICF signed for: rapid test collection, comorbidity questionnaire and clinical evaluation; and if leprosy diagnosis is confirmed, collection of complementary exams.\n\nExclusion Criteria:\n\n(I) Municipalities\n\n* Municipality with extreme population size (municipalities with a number of inhabitants lower than the 10th percentile and higher than the 90th percentile).\n* Municipality with operational epidemiological classification by the BMoH as: 'municipalities without cases in the period 2015 to 2019'.\n* Municipalities with active or recent participation (less than one year) in other active-finding strategies, in addition to the usual ones: ministerial, Non-Governmental Organizations (NGOs), academic, among others.\n\n(II) Primary Health Units\n\n* UBS with limited multidisciplinary team (absence of physicians, nurse and\u002For community health agents).\n* UBS with difficult access (no access by land, i.e. riverside populations).\n* UBS with territorial coverage exclusively of indigenous populations.\n\n(III) Participants\n\n* LSQ negative.\n* Patients with a previous diagnosis or history of treated leprosy.\n* Patients residing\u002Fregistered outside the selected municipality.",true,{"count":64,"type":20},1925,"INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to assess whether a multifactorial active case-finding strategy improves the detection of leprosy cases in Brazil compared to usual screening practices. The main questions it aims to answer are:\n\n\\- Does the intervention increase the number of new leprosy cases detected compared to standard care?\n\nParticipants will:\n\n* Receive community awareness about leprosy.\n* Be screened using the Leprosy Suspicion Questionnaire at priority areas identified by georeference tools.\n* Undergo clinical evaluation by a trained medical team.\n* If leprosy is diagnosed, affected patients will collect complementary laboratory exams\n\nHealthcare professionals from primary care units will receive training in leprosy, while researchers will monitor changes in leprosy incidence over a 12-month period using data from Brazil's national notification system. The study will provide insights into underdiagnosis and the clinical profiles of patients who have been diagnosed.",[70],"Leprosy",[70,72,73,74,39],"Active-case finding","Cluster stepped-wedge","Clinical trial","2026-04-26",{"date":77,"type":45},"2026-04-28",{"date":79,"type":45},"2025-06-01",{"date":81,"type":20},"2026-05-31",{"name":51,"class":52},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":65,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":83},"100600397","implementation-of-the-start-intervention-in-brazil-a-controlled-feasibility-trial-100600397","NCT07096960","Implementation of the START Intervention in Brazil: a Controlled Feasibility Trial","A Brazilian Version of the STrAtegies for RelaTives (START) Intervention in the Unified Health System (SUS): a Controlled Feasibility Trial","START\u002FESCADA","Inclusion Criteria:\n\n* Informal caregivers (≥18 years old) who are the primary or one of the primary persons responsible for caring for a family member with dementia, providing regular and sustained emotional or practical support every week, and living in the same household or nearby with frequent face-to-face interaction.\n* Care recipient (person with dementia) with Clinical Dementia Rating (CDR) score ≥1.\n* Care recipient with at least one ICD-10 dementia diagnosis code documented in their medical record.\n\nExclusion criteria:\n\n* Illiterate caregivers.\n* Caregivers who provide only occasional or sporadic support (less than weekly or without regular caregiving responsibility).\n* Care recipients who are institutionalized (e.g., living in long-term care facilities).",{"count":93,"type":20},90,[67],"This controlled trial aims to assess the feasibility of a culturally adapted Brazilian version of the START (STrAtegies for RelaTives) program, a structured coping strategy program designed for family caregivers of people living with dementia. The program will be delivered by trained community general health workers (CGHW) in 10 municipalities across Brazil. Outcomes will include measures of feasibility and acceptability, as well as caregiver burden, mental health, and quality of life, assessed at baseline and after 6 months.",[97],"Caregiver Burden of People With Dementia","2025-07-29",{"date":100,"type":45},"2025-07-31",{"date":102,"type":45},"2025-07-01",{"date":104,"type":20},"2026-12-31",{"name":51,"class":52},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":65,"phases":116,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100439315","chemoradiation-and-consolidation-chemotherapy-with-or-without-oxaliplatin-for-distal-rectal-cancer-and-watch-and-wait-100439315","NCT05000697","Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait","Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait. A Multi-center Prospective Randomized Controlled Trial. (CCHOWW)","CCHOWW","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. ECOG 0-2 or KPS≥70;\n3. Primary rectal adenocarcinoma (biopsy confirmed) within the reach of digital rectal examination (at least lower tip\u002Fborder) by the attending colorectal surgeon;\n4. Endoscopic documentation;\n5. Abdominal and chest CT scans showing no evidence of metastatic disease;\n6. High-resolution magnetic resonance images performed at either 1.5T or 3.0T system using a phased array surface coil with: sagittal T2 images including the anal verge and the sacrum; axial oblique T2 weighted images acquired in a plane perpendicular to the long axis of the rectal wall guided by the sagittal images; coronal images acquired in parallel to the anal canal plane. Small field of view (16-18cm), 3mm section thickness, increased matrix size and increased number of signal averages are required;\n7. Radiological defining criteria (centralized):\n\n   1. Lower edge of tumor at the level (max. 1cm distance) or below the anorectal ring defined at sagittal or coronal views;\n   2. mrT2, mrT3 (any subclassification)\n   3. mrN0-1 (≤3 radiologically positive lymph nodes)\n   4. mrEMVI: any status\n   5. mrMRF: any status\n\nExclusion Criteria:\n\n1. Pregnancy\n2. ECOG ≥3 or KPS\\\u003C70\n3. Unwilling to consent\n4. Metastatic disease (any kind; internal iliac and obturator nodes are considered local disease and not metastatic disease and therefore will not be considered as exclusion criteria)\n5. mrT4 or mrN2\n6. Previous pelvic irradiation\n7. Baseline neuropathy\n8. Receiving treatment of other anti-cancer drug or methods\n9. Presence of uncontrolled life threatening diseases",{"count":115,"type":20},216,[67],"Background: Neoadjuvant chemoradiation (nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer. Advantages of this approach include improved local control after radical surgery but also the opportunity for organ preserving strategies (Watch and Wait - WW). Consolidation chemotherapy (cCT) regimens using fluoropyrimidine-based with or without oxaliplatin following nCRT have demonstrated to increase complete response and organ preservation rates among these patients. However, the benefit of adding oxaliplatin to cCt compared to fluoropyrimidine alone regimens in terms of primary tumor response remains unclear. Since oxaliplatin-treatment may be associated with considerable toxicity, it becomes imperative to understand the benefit of its incorporation into standard cCT regimens in terms of primary tumor response. The aim of the present trial is to compare the outcomes of 2 different cCT regimens following nCRT (fluoropyrimidine-alone versus fluoropyrimidine+oxaliplatin) for patients with distal rectal cancer.\n\nMethods: In this multi-centre study, patients with magnetic resonance-defined distal rectal tumors will be randomized on a 1:1 ratio to receive long-course chemoradiation (54Gy) followed by cCT with fluoropyrimidine alone versus fluoropyrimidine+oxaliplatin. Magnetic resonance (MR) will be analyzed centrally prior to patient inclusion and randomization. mrT2-3N0-1 tumor located no more than 1cm above the anorectal ring determined by sagittal views on MR will be eligible for the study. Tumor response will be assessed after 12 weeks from radiotherapy (RT) completion. Patients with clinical complete response (clinical, endoscopic and radiological) will be enrolled in an organ-preservation program (WW). The primary endpoint of this trial is decision to organ-preservation surveillance (WW) at 18 weeks from RT completion.\n\nDiscussion: Long-course nCRT with cCT is associated with improved complete response rates and may be a very attractive alternative to increase the chances for organ-preservation strategies. Fluoropyrimidine-based cCT with or without oxaliplatin has never been investigated in the setting of a randomized trial to compare clinical response rates and the possibility of organ-preservation. The outcomes of this study may significantly impact clinical practice of patients with distal rectal cancer interested in organ-preservation.",[119,120],"Rectal Cancer","Consolidation",[122,123,124,125],"Rectal cancer","Consolidation Chemotherapy","Complete Response","Watch and Wait","2024-11-25",{"date":128,"type":45},"2024-11-27",{"date":130,"type":45},"2021-07-14",{"date":132,"type":20},"2027-04",{"name":51,"class":52},24,""]